Gene-editing specialist Seamless Therapeutics has attracted its first major pharma partner, Eli Lilly, with a $1.12 billion alliance that will seek out therapies for hearing loss.
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results